We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.
- Authors
Schüler-Toprak, Susanne; Moehle, Christoph; Skrzypczak, Maciej; Ortmann, Olaf; Treeck, Oliver
- Abstract
<bold>Background: </bold>Estrogen receptor (ER) β has been suggested to affect ovarian carcinogenesis. We examined the effects of four ERβ agonists on proliferation and gene expression of two ovarian cancer cell lines.<bold>Methods: </bold>OVCAR-3 and OAW-42 ovarian cancer cells were treated with the ERβ agonists ERB-041, WAY200070, Liquiritigenin and 3β-Adiol and cell growth was measured by means of the Cell Titer Blue Assay (Promega). ERβ expression was knocked down by transfection with specific siRNA. Additionally, transcriptome analyses were performed by means of Affymetrix GeneChip arrays. To confirm the results of DNA microarray analysis, Western blot experiments were performed.<bold>Results: </bold>All ERβ agonists tested significantly decreased proliferation of OVCAR-3 and OAW-42 cells at a concentration of 10 nM. Maximum antiproliferative effects were induced by flavonoid Liquiritigenin, which inhibited growth of OVCAR-3 cells by 31.2% after 5 days of treatment, and ERB-041 suppressing proliferation of the same cell line by 29.1%. In OAW-42 cells, maximum effects were observed after treatment with the ERβ agonist WAY200070, inhibiting cell growth by 26.8%, whereas ERB-041 decreased proliferation by 24.4%. In turn, knockdown of ERβ with specific siRNA increased cell growth of OAW-42 cells about 1.9-fold. Transcriptome analyses revealed a set of genes regulated by ERβ agonists including ND6, LCN1 and PTCH2, providing possible molecular mechanisms underlying the observed antiproliferative effects.<bold>Conclusion: </bold>In conclusion, the observed growth-inhibitory effects of all ERβ agonists on ovarian cancer cell lines in vitro encourage further studies to test their possible use in the clinical setting.
- Subjects
ESTROGEN receptors; GENE expression; OVARIAN cancer; CANCER cells; SMALL interfering RNA; ESTROGEN replacement therapy; ANTINEOPLASTIC agents; CELL lines; CELL physiology; ESTROGEN; GENES; OVARIAN tumors; HETEROCYCLIC compounds; PHENOLS; PROTEINS; GENE expression profiling; FLAVANONES; PHARMACODYNAMICS; THERAPEUTICS
- Publication
BMC Cancer, 2017, Vol 17, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-017-3246-0